Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Qingdao: Insulin Pump Follow-Up Program

19. dubna 2019 aktualizováno: Medtronic Diabetes

Qingdao: Insulin Pump Follow-up Program

The purpose of the study is to observe/ collect clinical data, subject users' feedback, and device data to better understand the real-life usage and acceptance of the 722 Pump in type 1 diabetes subjects,<18 years of age, and the role of insulin pump therapy in Qingdao,China.

Přehled studie

Postavení

Ukončeno

Podmínky

Detailní popis

This is a prospective, multi-center, non-randomized and noninterventional post-market release study. Subjects will participate in 2 phases with each phase requiring the subject to use the continuous subcutaneous insulin infusion (CSII) pump over the course of the study. During the study, subjects and parent or legal guardian will be trained to wear the glucose sensor in the abdominal area for 3 days to transmit real-time (RT) data to the pump. The duration of each study phase is approximately 6 months.

Typ studie

Pozorovací

Zápis (Aktuální)

16

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Čína
    • Shandong
      • Qingdao, Shandong, Čína
        • The Affiliated Hospital of Qingdao University

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

Ne starší než 18 let (Dítě, Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

A total of approximately 100 subjects (age<18 years) will be enrolled by up to 10 investigational centers to complete 13 scheduled study visits in the study.

Popis

Inclusion Criteria:

  • Subject is age < 18 years at time of screening
  • Subject has a clinical diagnosis of type 1 diabetes
  • Subject is willing to perform required sensor calibrations
  • Subject is willing to wear the Medtronic MiniMed Paradigm® REAL Time System continuously throughout the study
  • Subject is a participant in the Qingdao project.

Exclusion Criteria:

  • Subject is actively participating in an investigational study (drug or device) wherein he/she has received diabetes treatment from an investigational study drug or investigational study devices in the last 2 weeks
  • Subject has known hypersensitivity to insulin or insulin infusion set(including tape)

  • Subject has used the insulin pump and/or real time CGM/sensor within 90 days before the screening visit for more than 10 days in the outpatient setting:

    • For example, subjects who have used insulin pump and/or real time CGM/sensor in the inpatient setting will still be eligible for enrollment.
    • For example, subjects who have used insulin pump and/or real time CGM/sensor for 8 days in the outpatient setting within 90 days before screening visit will still be eligible for enrollment.
    • For example, subjects who have worn the insulin pump and/or real time CGM/sensor for 3 months in the outpatient setting a year before the screening visit will still be eligible for enrollment
  • Subject has been treated with drugs with a known effect on BG within 8 weeks before enrollment other than diabetes medications such as insulin or oral anti-diabetic agents.
  • Subject has any systemic disease or medical condition found on screening that may interfere with the safety of the patient and efficacy of the study treatment, in the opinion of the Investigator, may preclude him/her from participating in the study.
  • Subject is being treated for hyperthyroidism at time of screening
  • Subject has taken any oral, injectable, or IV steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
  • Subject is currently abusing alcohol9. Any condition that either the Investigator believes would interfere with study participation or evaluation of results.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Medtronic MiniMed Paradigm® REAL-Time System
Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Glycosylated Hemoglobin (A1C)
Časové okno: Change in A1C from baseline to end of study (1 year)
The change of A1C from baseline to end of study (1 year) will be presented
Change in A1C from baseline to end of study (1 year)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Average Glucose Values Based on Continuous Glucose Monitoring Data
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
The average glucose value of all available glucose value of each subject for each evaluation period is calculated, and we present the mean and std of the individual average glucose value for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Standard Deviation of Glucose Value Based on Continuous Glucose Monitoring Data
Časové okno: Data is collected 7 days following the end of each period (At end of month 3, no glucose data is collected.).
The standard deviation of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual standard deviation for each evaluation period.
Data is collected 7 days following the end of each period (At end of month 3, no glucose data is collected.).
Coefficient of Variation of Glucose Value Per Each Subject Based on Continuous Glucose Monitoring Data
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
The coefficient of variation of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual coefficient of variation for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Mean Amplitude of Glycemic Excursion Based on Continuous Glucose Monitoring Data
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Mean Amplitude of Glycemic Excursion (which is often used to characterize glycemic variability, to know the detail of calculation, please refer to "Glucose Variability, © 2013 by the American Diabetes Association." ) of each subject for each evaluation period is calculated, and then we present the mean and std of the individual Mean Amplitude of Glycemic Excursion for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Number of Events in the Hypoglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Number of events in the hypoglycemic range (SG≤3.9mmol/L) of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual number of events for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Number of Events in the Hyperglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Number of Events in the Hyperglycemic Range (SG≥10.0 mmol/L) of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual number of events for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Area Under Curve in the Hypoglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Area under Curve in the hypoglycemic range (SG≤3.9mmol/L) of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual Area under Curve for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Area Under Curve in the Hyperglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Area under Curve in the hyperglycemic range (SG≥10.0 mmol/L) based on all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual Area under Curve for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Percentage of Time in the Hypoglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Percentage of time in the hypoglycemic range (SG ≤ 3.9 mmol/L) of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual percetage of time in that range for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Percentage of Time in the Hyperglycemic Range
Časové okno: Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).
Percentage of time in the hyperglycemic range (SG≥10.0 mmol/L) of all available glucose value of each subject for each evaluation period is calculated, and then we present the mean and std of the individual percentage of time in that range for each evaluation period.
Data is collected during the 7 days following the end of each period (At end of month 3, no glucose data is collected).

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Medtronic Diabetes

Vyšetřovatelé

  • Vrchní vyšetřovatel: Tang Li, The Affiliated Hospital of Qingdao University
  • Vrchní vyšetřovatel: chunbin Wang, Chinese People's Liberation Army 401 Hospital
  • Vrchní vyšetřovatel: Yamie Zhu, Qingdao Endocrine and Diabetes Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. dubna 2015

Primární dokončení (Aktuální)

1. září 2016

Dokončení studie (Aktuální)

1. září 2016

Termíny zápisu do studia

První předloženo

18. prosince 2015

První předloženo, které splnilo kritéria kontroly kvality

12. ledna 2016

První zveřejněno (Odhad)

14. ledna 2016

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

11. července 2019

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

19. dubna 2019

Naposledy ověřeno

1. dubna 2019

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • CEP303

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Diabetes typu 1

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Azerbaijan

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

3
Předplatit